NetWorth
LeaderPortfolio
Rubiralta
Jordi Rubiralta
Rank #2748
SPAIN•Healthcare•Diagnostics

Jordi Rubiralta

Net Worth
$1.387B
+0.08% (24h)
Jordi Rubiralta is a Spanish billionaire deriving his wealth from Werfen, a global leader in in vitro diagnostics. As a member of the board, and formerly the chairman, Rubiralta has played a key role in the company's expansion, including acquisitions in the US and Germany. His career in the healthcare diagnostics industry has led to a net worth of $1.4 billion as of March 2026, solidifying his position among the world's wealthiest individuals.

How to read Jordi Rubiralta's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Jordi Rubiralta, we anchor the narrative to Diagnostics and Diagnostics, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $1.387B alongside global rank #2748, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (SPAIN) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Jordi Rubiralta, a Spanish citizen, is part of the Rubiralta family, known for their significant presence in the diagnostics industry. The family's roots in business trace back to Josep María Rubiralta and Francisco Rubiralta, who founded a health products distribution company, Izasa, in 1966, which later evolved into Werfen.

Rise to Success

Jordi Rubiralta, along with his brothers, has been instrumental in the growth and success of Werfen. He served as the chairman of Werfen until 2019. Werfen has become a global leader in in vitro diagnostics, specializing in Hemostasis, Acute Care Diagnostics, and Autoimmunity. The company's success is reflected in its significant revenue and market share in key diagnostic areas. Jordi Rubiralta's leadership helped Werfen expand, particularly through acquisitions in the United States and Germany, including Tem and Accriva Diagnostics.

Key Business Strategies

The family's strategy has focused on specialization, innovation, and controlled expansion, particularly in high-complexity areas of diagnostics. Werfen's focus on advanced diagnostics has set it apart. His family office, Yukon Capital, has engaged in high-profile real estate transactions in Spain, further diversifying the family's business interests. Since 2013, Jordi Rubiralta has been a board member and was previously the chairman of Werfen until 2019.

Philanthropy

Details on Rubiralta's specific philanthropic endeavors are currently unavailable.

Career Timeline

2019

President of Family Council

Assumed the role of President of the Family Council, coordinating business activities.

2013

Board Member

Became a member of the board of directors at Werfen.

2012

President of Werfen

Appointed President of Werfen, leading the company's global expansion.

Philanthropic Impact

Unknown$XB

Unknown

Details on Rubiralta's philanthropic endeavors are currently unavailable.

Key Business Ventures & Holdings

CompanyStakeValue
Werfen——

Net Worth History

In-Depth Analysis

Early Life

Jordi Rubiralta, a Spanish citizen, is part of the Rubiralta family, known for their significant presence in the diagnostics industry. The family's roots in business trace back to Josep María Rubiralta and Francisco Rubiralta, who founded a health products distribution company, Izasa, in 1966, which later evolved into Werfen.

Rise to Success

Jordi Rubiralta, along with his brothers, has been instrumental in the growth and success of Werfen. He served as the chairman of Werfen until 2019. Werfen has become a global leader in in vitro diagnostics, specializing in Hemostasis, Acute Care Diagnostics, and Autoimmunity. The company's success is reflected in its significant revenue and market share in key diagnostic areas. Jordi Rubiralta's leadership helped Werfen expand, particularly through acquisitions in the United States and Germany, including Tem and Accriva Diagnostics.

Key Business Strategies

The family's strategy has focused on specialization, innovation, and controlled expansion, particularly in high-complexity areas of diagnostics. Werfen's focus on advanced diagnostics has set it apart. His family office, Yukon Capital, has engaged in high-profile real estate transactions in Spain, further diversifying the family's business interests. Since 2013, Jordi Rubiralta has been a board member and was previously the chairman of Werfen until 2019.

Philanthropy

Details on Rubiralta's specific philanthropic endeavors are currently unavailable.

Data Sources & Methodology

Figures for Jordi Rubiralta are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom